Cramer's 'Mad Money' Recap: The Bulls Are Back
Click here for an archive of Cramer's "Mad Money" recaps.
"The big news today isn't that stocks rallied," Jim Cramer told viewers of his "Mad Money" TV show Tuesday.
Rather, he said the takeaway from the day's market surge should be that his five long-term bull market theses sprang to life.Until now, aerospace and defense stocks have been weighed down by delays in Boeing's (BA) new Dreamliner. But Cramer said Boeing's announcement Tuesday that the Dreamliner is back on track should allow the whole sector to rally once again.
China's Insatiable Demand"I'm a Taco Bell kind of guy, a KFC kind of guy and a Pizza Hut kind of guy," Cramer told viewers as he welcomed David Novak, President and CEO of Yum! Brands (YUM) to the show. Cramer called Yum! Brands one of the most pro-shareholder, pro-growth companies out there. Novak talked about the company's strong growth in China, where Yum! Brands is opening almost one store a day in the country. He said that Yum! offers a full line of products in China and that the Chinese people are responding well to their brands. He also said his company is prepared for a big pickup in business when the Olympics comes to China later this year. Despite incredible growth in China, Novak said the company is also aggressively growing in Russia, India and other emerging markets. Domestically, Novak said Yum! has some work to do to drive sales at its 20,000 outlets. He believes it can be done by going beyond what it traditionally serves to offering desserts, beverages and healthier foods. "If McDonald's (MCD) can turn around its sales, so can Yum! Brands," he said. He owns McDonald's for
One on One With Schering-Plough CEO Fred HassanCramer sat down with Fred Hassan, Chairman and CEO of Schering-Plough (SGP), to talk about the company's recent earnings and questions regarding its controversial anti-cholesterol drug Vytorin. According to Hassan, the company is a lot stronger than the market gives them credit for. The analysts, he said, tend to focus only on the US sales and forget about the company's global presence. Asked about a recent study on the effectiveness of Vytorin, Hassan responded by saying that he stands behind the drug's ability to lower bad cholesterol. He downplayed the study as small and unrepresentative of the mainstream market. He also noted the drug's safety and tolerability levels were normal.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV